Caixin
BUSINESS & TECH

Celgene to Take Stake in Chinese Biotech Peer BeiGene

A view of a Celgene facility in San Diego, the U.S., in January 2016. Photo: IC
A view of a Celgene facility in San Diego, the U.S., in January 2016. Photo: IC

(Beijing) — U.S. biopharmaceutical company Celgene Corp. plans to acquire an equity stake in Chinese peer BeiGene Ltd. to help commercialize BeiGene’s solid-tumor cancer treatment in markets outside Asia.

Celgene plans to hold a 5.9% share in BeiGene for nearly $150 million and pay upfront licensing fees totaling $263 million. The Chinese biotechnology developer will be eligible to receive up to $980 million in development, regulatory and sales milestone payments, the companies said in a joint statement on Wednesday.

ladingImg
You've accessed an article available only to subscribers
Try 4 weeks for $0.99
SUBSCRIBE
Share this article
Open WeChat and scan the QR code
Copyright © 2017 Caixin Global Limited. All Rights Reserved.